SCHEMBL2138523

SCHEMBL2138523

CCCCCC(CC)(CC)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
AKR1B1 P15121 1/20 0.42
CES2 O00748 1/20 0.42
GPR84 Q9NQS5 7/20 0.41
PPARG P37231 6/20 0.41
PPARD Q03181 6/20 0.41
PPARA Q07869 6/20 0.41
HDAC11 Q96DB2 5/20 0.41
TSHR P16473 4/20 0.41
ALDH1A1 P00352 2/20 0.41
TLR2 O60603 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
FABP4 P15090 2/20 0.41
PTPN1 P18031 2/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
MEN1 O00255 1/20 0.41
ESR1 P03372 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680659 0.98 CYP4F2 (0.41) CYP4F2CYP4A11AKR1B1CES2GPR84
SCHEMBL2141772 0.98 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL8919538 0.98 CYP4F2 (0.41) CYP4F2CYP4A11AKR1B1CES2GPR84
SCHEMBL5049746 0.98 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL5046725 0.98 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL20915260 0.98 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL20936507 0.98 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL20915383 0.98 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL20936490 0.98 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL313593 0.98 CES2 (0.45) CES2GPR84PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2504099-B1 HYDROPROCESSING BULK CATALYST, IT'S USE AND METHODS OF MAKING THEREOF CHEVRON USA INC (US) 2021-08-11 EP claimed
EP-1722741-B1 DENTAL MATERIAL BASED ON ALKOXYSILYL-FUNCTIONAL POLYETHERS KETTENBACH GMBH & CO KG (DE) 2009-04-01 EP claimed
US-20070173557-A1 Dental material based on alkoxysilyl-functional polyethers containing a salt of a strong base as catalyst KETTENBACH GMBH & CO. KG (DE) 2007-07-26 US claimed
EP-1722741-A1 DENTAL MATERIAL BASED ON ALKOXYSILYL-FUNCTIONAL POLYETHERS Kettenbach GmbH & CO. KG (DE) 2006-11-22 EP claimed
WO-2005077321-A1 DENTAL MATERIAL BASED ON ALKOXYSILYL-FUNCTIONAL POLYETHERS KETTENBACH GMBH & CO. KG (DE) 2005-08-25 WO claimed
US-20180177760-A1 COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS SPRIASO LLC (US) 2018-06-28 US disclosed
US-9956201-B2 Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms SPRIASO LLC (US) 2018-05-01 US disclosed
US-20160015684-A1 COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS SPRIASO LLC 2016-01-21 US disclosed
US-20160016887-A1 Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins SPRIASO LLC 2016-01-21 US disclosed
EP-1738737-B1 Dimensionally stable articles from cured condensation-crosslinked dental material KETTENBACH GMBH & CO KG (DE) 2012-05-16 EP disclosed
US-7902269-B2 Dental material based on alkoxysilyl-functional polyethers containing a salt of a strong base as catalyst KETTENBACH GMBH & CO. KG (DE) 2011-03-08 US disclosed
US-7790781-B2 Condensation-crosslinkable dental material hardening to dimensionally stable casts KETTENBACH GMBH & CO. KG (DE) 2010-09-07 US disclosed
CN-1230536-A Process for producing lanthanide metal carboxylate QIMEI IND CO LTD (CN) 1999-10-06 CN disclosed
EP-0512346-B1 Process for preparing metal carboxylates and their use in the polymerisation of monomers suitable for the Ziegler-Natta polymerisation BAYER AG (DE) 1995-06-28 EP disclosed
US-5220045-A PROCESS FOR THE PRODUCTION OF METAL CARBOXYLATES AND THEIR USE FOR THE POLYMERIZATION OF MONOMERS SUITABLE FOR ZIEGLER-NATTA POLYMERIZATION BAYER AKTIENGESELLSCHAFT (DE) 1993-06-15 US disclosed
EP-0512346-A2 Process for preparing metal carboxylates and their use in the polymerisation of monomers suitable for the Ziegler-Natta polymerisation BAYER AG (DE) 1992-11-11 EP disclosed
EP-0011184-B2 CATALYST, ITS MANUFACTURE AND ITS USE IN THE SOLUTION-POLYMERISATION OF CONJUGATED DIENES BAYER AG (DE) 1988-05-18 EP disclosed
EP-0011184-B1 CATALYST, ITS MANUFACTURE AND ITS USE IN THE SOLUTION-POLYMERISATION OF CONJUGATED DIENES BAYER AG (DE) 1983-05-11 EP disclosed
EP-0011184-A1 Catalyst, its manufacture and its use in the solution-polymerisation of conjugated dienes BAYER AG (DE) 1980-05-28 EP disclosed
US-4104141-A Electrochemical oxidation of alkoxy-substituted aromatic compounds UOP INC. (US) 1978-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173557-A1 Dental material based on alkoxysilyl-functional polyethers containing a salt of a strong base as catalyst CSNK1A1L, TBL3, DCLK3 CYP4F2 4665/4885CYP4A11 4397/4885AKR1B1 3278/4885
US-20160016887-A1 Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins SLC7A1, CYP2D6, SLC19A1 CYP4F2 84/4885CYP4A11 125/4885AKR1B1 386/4885
US-20160015684-A1 COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS SLC7A1, CYP2D6, CYP3A7 CYP4F2 24/4885CYP4A11 58/4885AKR1B1 413/4885
US-20180177760-A1 COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS SLC7A1, CYP2D6, CYP3A7 CYP4F2 32/4885CYP4A11 70/4885AKR1B1 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.